Cargando…

Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?

Enrollment in metastatic breast cancer trials usually requires measurable lesions, but patients with invasive lobular carcinoma (ILC) tend to form diffuse disease. We found that the proportion of patients with metastatic ILC enrolled in clinical trials at our institution was significantly lower than...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abel, Mary Kathryn, Melisko, Michelle E., Rugo, Hope S., Chien, A. Jo, Diaz, Italia, Levine, Julia K., Griffin, Ann, McGuire, Joseph, Esserman, Laura J., Borno, Hala T., Mukhtar, Rita A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Brief Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8547221/ https://www.ncbi.nlm.nih.gov/pubmed/34697300 http://dx.doi.org/10.1038/s41523-021-00348-z

Ejemplares similares

The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study
por: Abel, Mary Kathryn, et al.
Publicado: (2022)

Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer
por: Record, Helena, et al.
Publicado: (2023)

The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database
por: Rothschild, Harriet T, et al.
Publicado: (2023)

The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study
por: Abel, Mary Kathryn, et al.
Publicado: (2021)

ASO Author Reflections: Discordant Clinical and Molecular Risk in Invasive Lobular Carcinoma of the Breast: The 21-Gene Recurrence Score in the National Cancer Database by Histologic Subtype
por: Abel, Mary Kathryn, et al.
Publicado: (2022)

How current reporting practices may mask differences: A call for examining cancer-specific demographic enrollment patterns in cancer treatment clinical trials
por: Borno, Hala T., et al.
Publicado: (2019)

4314 The Impact of Axillary Surgery on Recurrence-Free Survival in Invasive Lobular Carcinoma (ILC) of the Breast
por: Abel, Mary Kathryn Reed, et al.
Publicado: (2020)

Amelioration of sexual adverse effects in the early breast cancer patient
por: Melisko, Michelle E., et al.
Publicado: (2010)

RECIST Applied to Realistic Tumor Models
por: Levine, Zachary H., et al.
Publicado: (2011)

RECIST rules
por: Sohaib, Aslam
Publicado: (2012)

Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma
por: Abel, Mary Kathryn, et al.
Publicado: (2021)

Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast
por: Piper, Merisa L., et al.
Publicado: (2019)

RECIST revised: implications for the radiologist. A review article on the modified RECIST guideline
por: van Persijn van Meerten, Els L., et al.
Publicado: (2009)

Evaluation of the Pathways for Survivors Program to Address Breast Cancer Survivorship–Associated Distress: Survey Study
por: Umashankar, Saumya, et al.
Publicado: (2022)

Invasive lobular carcinoma: clinicopathological features and subtypes
por: Danzinger, Sabine, et al.
Publicado: (2021)

iRECIST: how to do it
por: Persigehl, Thorsten, et al.
Publicado: (2020)

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival
por: Manitz, Juliane, et al.
Publicado: (2022)

Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy
por: Rothschild, Harriet T., et al.
Publicado: (2023)

Response Evaluation and Survival Prediction Following PD‐1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria
por: Zhou, Meng, et al.
Publicado: (2021)

Comparison of RECIST 1.0 and RECIST 1.1 in Patients with Metastatic Cancer: A Pooled Analysis
por: Kim, Jung Han, et al.
Publicado: (2015)

Invasive lobular carcinomas of the breast--the prognosis of histopathological subtypes.
por: du Toit, R. S., et al.
Publicado: (1989)

Area Deprivation Index in Patients with Invasive Lobular Carcinoma of the Breast: Associations with Tumor Characteristics and Outcomes
por: Kaur, Mandeep, et al.
Publicado: (2023)

Imaging tumour response: beyond RECIST
por: Koh, Dow-Mu
Publicado: (2014)

A case report of vanishing bile duct syndrome after exposure to pexidartinib (PLX3397) and paclitaxel
por: Piawah, Sorbarikor, et al.
Publicado: (2019)

Comparison of the RECIST 1.0 and RECIST 1.1 in Non-Small Cell Lung Cancer Treated with Cytotoxic Chemotherapy
por: Choi, Hyun Chang, et al.
Publicado: (2015)

Comparison of the RECIST 1.0 and RECIST 1.1 in patients treated with targeted agents: a pooled analysis and review
por: Kim, Jung Han
Publicado: (2016)

Invasive lobular carcinoma of the breast: the increasing importance of this special subtype
por: McCart Reed, Amy E., et al.
Publicado: (2021)

Response assessment in metronomic chemotherapy: RECIST or PERCIST?
por: Agrawal, Archi, et al.
Publicado: (2014)

RECIST criteria: our experience in daily practice
por: De Luca, S, et al.
Publicado: (2015)

A Letter in Support of Real-World RECIST
por: Gajra, Ajeet, et al.
Publicado: (2020)

Inter‐observer agreement for the histological diagnosis of invasive lobular breast carcinoma
por: Christgen, Matthias, et al.
Publicado: (2021)

Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Park, Hyo Jung, et al.
Publicado: (2021)

Lobular breast cancer - the most common special subtype or a most special common subtype?
por: Lehmann, Ulrich
Publicado: (2015)

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602
por: Sato, Yozo, et al.
Publicado: (2013)

FGFR4 overexpression and hotspot mutations in metastatic ER+ breast cancer are enriched in the lobular subtype
por: Levine, Kevin M., et al.
Publicado: (2019)

Imaging beyond RECIST: CT and MRI in molecular therapies
por: Diederich, Stefan
Publicado: (2012)

Response assessment in daily practice: RECIST and its modifications
por: Sohaib, Aslam
Publicado: (2014)

Imaging biomarkers for evaluating tumor response: RECIST and beyond
por: Ko, Ching-Chung, et al.
Publicado: (2021)

Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer
por: Rothschild, Harriet T., et al.
Publicado: (2021)

Patterns of response in metastatic NSCLC during PD‐1 or PD‐L1 inhibitor therapy: Comparison of the RECIST 1.1 and iRECIST criteria
por: Liang, Hongge, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_u50n7qm3eg9f97kbj6to9epr4f